Loading...
PolarityTE, Inc.
PTE•NASDAQ
Healthcare
Biotechnology
$0.24
$-0.00(-0.82%)

The company's financials show resilient growth, with revenue advancing from $73000.00 in Q2 2022 to $0.00 in Q1 2023. Gross profit remained healthy with margins at N/A in Q1 2023 compared to -71% in Q2 2022. Operating income hit -$4.80M last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$5.07M. Net income dropped to -$3.24M, while earnings per share reached -$0.44. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan